Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Broadcom Inc (AVGO) Price & Performance

Adaptive Biotechnologies CorpTrade
Broadcom IncTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Broadcom Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.14 (market cap $4.04B), while Broadcom Inc trades at $422.14 (market cap $1.98T). The key difference: Broadcom Inc is far larger — about 490.1× Adaptive Biotechnologies Corp's market cap, and Broadcom Inc pays a 0.62% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.

ADPTAVGO
Market Cap
$4.04B$1.98T
Sector
HealthTechnology
52-Week High
$25.45$481.57
52-Week Low
$12.30$289.60
Enterprise Value
$4.10B$2.02T
Dividend Yield
0.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.

Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.

Broadcom Inc

Broadcom (AVGO) trades at $422.4, down 1.25% on the day, but maintains a bullish technical trend with strong support at $418. The company reported robust earnings, beating estimates for three consecutive quarters, with Q1 2026 EPS of $2.44 exceeding the $2.40 forecast. Revenue growth accelerated to $63.89 billion in 2025, up from $51.6 billion in 2024, while net income surged to $23.13 billion. Valuation multiples remain elevated with a P/E of 69.23, reflecting high investor expectations for AI-driven growth.

Outlook remains positive given strong AI revenue projections exceeding $100 billion by 2027, but high valuation and dependence on a few large customers pose risks. Analyst consensus is overwhelmingly bullish with 86% buy ratings and a $510.21 price target, suggesting 21% upside. Competitive pressures in the semiconductor space and macroeconomic volatility are key watchpoints for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Broadcom Inc

Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.

Read more on AVGO